A clinical trial being conducted in Montana might pave the way in a breakthrough in the fight against mesothelioma. The trial has so far involved using a patient's immune system T cells to combat a rare cancer. This is a form of immunotherapy known as adoptive cell transfer.Mesothelioma is difficult to attack because it overwhelms the immune system so fast, however immunotherapy stimulates the immune system directly against mesothelioma cells meaning that there should be less side effects than with current treatments available to cancer sufferers. The clinical trial has now been widened to encompass mesothelioma patients.
You can read more about this story here
Peter Williams, Head of Asbestos Claims at Fieldfisher says: "It is encouraging to hear stories like this, mesothelioma is an aggressive cancer that works fast and in general life expectancy for people with this cancer is very poor – the current treatments often rely on the sufferer being able to withstand the side effects. Any treatment that can stop or slow the effects and give the patient a better quality of life is to be welcomed."
Peter Williams LinkedIn
Peter Williams Google+